Bolt Biotherapeutics Q2 EPS $(4.57) Misses $(2.88) Estimate, Sales $5.000K Miss $500.000K Estimate
Bolt Biotherapeutics (NASDAQ: BOLT ) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent. This is a 2.47 percent decrease over losses of $(4.46) per share from the same period last year. The company reported quarterly sales of $5.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 99.00 percent. This is a 99.72 percent decrease over sales of $1.804 million the same period last year.
Bolt Biotherapeutics (NASDAQ: BOLT ) reported quarterly losses of $(4.57) per share which missed the analyst consensus estimate of $(2.88) by 58.68 percent.
This is a 2.47 percent decrease over losses of $(4.46) per share from the same period last year.
The company reported quarterly sales of $5.000 thousand which missed the analyst consensus estimate of $500.000 thousand by 99.00 percent.
This is a 99.72 percent decrease over sales of $1.804 million the same period last year.